Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma

Clinical Cancer Research

Volumn 15, Issue 4, 2009, Pages 1384-1392

  Helfrich, Iris ^a,c   Edler, Lutz ^b   Sucker, Antje ^b   Thomas, Markus ^a,e   Christian, Sven ^a,d   Schadendorf, Dirk ^b,c   Augustin, Hellmut G ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d BAYER PHARMA AG   (Germany)

^e ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; SMALL INTERFERING RNA; ANGIOPOIETIN RECEPTOR; NERVE GROWTH FACTOR; PROTEIN S 100; S 100 CALCIUM BINDING PROTEIN BETA SUBUNIT; S-100 CALCIUM-BINDING PROTEIN BETA SUBUNIT; TUMOR MARKER;

ADULT; ARTICLE; CANCER GROWTH; CANCER STAGING; CELL LINE; CELL MIGRATION; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR BIOPSY; TUMOR CELL; AGED; BLOOD; CELL CULTURE; CHEMISTRY; DISEASE COURSE; MIDDLE AGED; MORTALITY; PATHOLOGY; PHYSIOLOGY; SKIN TUMOR;

ADULT; AGED; ANGIOPOIETIN-2; CELLS, CULTURED; DISEASE PROGRESSION; ENDOTHELIAL CELLS; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NERVE GROWTH FACTORS; RECEPTOR, TIE-2; S100 PROTEINS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 63149188174     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1615     Document Type: Article

References (42)

1. Einspahr JG,ThomasTL, Saboda K, et al. Expression of vascular endothelial growth factor in early cutaneous melanocytic lesion progression. Cancer 2007;110: 2519-27.
2. Lee S, Chen TT, Barber CL, et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007; 130:691 -703.
3. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358:2039-49.
4. Mazure NM, Chen EY, Yeh P, Laderoute KR, Giaccia AJ. Oncogenic transformation and hypoxia synergisti- cally act to modulate vascular endothelial growth factor expression. Cancer Res 1996;56:3436-40.
5. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005:69 Suppl 3:4-10.
6. Alajati A, Laib AM, Weber H, et al. Spheroid- based engineering of a human vasculature in mice. Nat Methods 2008;5:439-45.
7. Pfaff D, Fiedler U, Augustin HG. Emerging roles of the angiopoietin-Tie and the ephrin-Eph systems as regulators of cell trafficking. J Leukoc Biol 2006;80: 719-26.
8. Bussolino F, Valdembri D, Caccavari F, Serini G. Semaphoring vascular morphogenesis. Endothelium 2006;13:81-91.
9. Andrae J, Gallini R, Betsholtz C. Role of platelet- derived growth factors in physiology and medicine. Genes Dev 2008;22:1276-312.
10. Fiedler U, Augustin HG. Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol 2006;27:552-8.
11. Suri C, Jones PF, Patan S, et al. Requisite role of angiopoietin-1, a ligand for theTIE2 receptor, during embryonic angiogenesis. Cell 1996:87:1171 -80.
12. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoie- tin-2, a natural antagonist forTie2 that disrupts in vivo angiogenesis. Science 1997;277:55-60.
13. Imhof BA, Aurrand-Lions M. Angiogenesis and inflammation face off. Nat Med 2006:12:171 -2.
14. Teichert-Kuliszewska K, Maisonpierre PC, Jones N, et al. Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. Cardiovasc Res 2001;49:659-70.
15. VlaykovaT, Laurila P, MuhonenT, et al. Prognostic value of tumour vascularity in metastatic melanoma and association of blood vessel density with vascular endothelial growth factor expression. Melanoma Res 1999;9:59-68.
16. DanielsenT, Rofstad EK. VEGF, bFGF and EGF in the angiogenesis of human melanoma xenografts. Int J Cancer 1998;76:836-41.
17. Neitzel LT, Neitzel CD, Magee KL, Malafa MP. Angiogenesis correlates with metastasis in melanoma. Ann Surg Oncol 1999;6:70-4.
18. Scharpfenecker M, Fiedler U, ReissY, Augustin HG. TheTie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J Cell Sci 2005:118:771 -80.
19. Fiedler U, Scharpfenecker M, Koidl S, et al. TheTie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 2004;103:4150-6.
20. Stratmann A, Risau W, Plate KH. Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 1998;153:1459-66.
21. Scholz A, Rehm VA, Rieke S, et al. Angiopoietin-2 serum levels are elevated in patients with liver cirrhosis and hepatocellular carcinoma. Am J Gastroenterol 2007;102:2471 -81.
22. Park JH, Park KJ, Kim YS, et al. Serumangiopoietin- 2 as a clinical marker for lung cancer. Chest 2007;132: 200-6.
23. Gu J, Yamamoto H, Ogawa M, et al. Hypoxia- induced up-regulation of angiopoietin-2 in colorectal cancer. Oncol Rep 2006;15:779-83.
24. Orfanos SE, Kotanidou A, Glynos C, et al. Angiopoietin-2 is increased in severe sepsis: correlation with inflammatory mediators. Crit Care Med 2007; 35:199-206.
25. Ugurel S, Bell N, Sucker A, Zimpfer A, Rittgen W, Schadendorf D. Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma. Int J Cancer 2005;117:825-30.
26. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635-48.
27. Holthorn T, Lausen B. Bagging tree classifiers for laser scanning images: a data- and simulation-based strategy. Artif Intell Med 2003;27:65-79.
28. Guo HB, Stoffel-Wagner B, Bierwirth T, Mezger J, Klingmuller D. Clinical significance of serum S100 in metastatic malignant melanoma. Eur J Cancer 1995; 31A:1898-902.
29. Hauschild A, Engel G, Brenner W, et al. Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy. Br J Dermatol 1999;140:1065-71.
30. Deichmann M, Benner A, Bock M, et al. S100-β, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 1999:17:1891 -6.
31. Garbe C, Leiter U, Ellwanger U, et al. Diagnostic value and prognostic significance of protein S-100β, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients. Cancer 2003;97:1737-45.
32. Birck A, Kirkin AF, Zeuthen J, Hou-Jensen K. Expression of basic fibroblast growth factor and vascular endothelial growth factor in primary and metastatic melanoma from the same patients. Melanoma Res1999;9:375-81.
33. Westphal JR, Van't Hullenaar R, Peek R, et al. Angiogenic balance in human melanoma: expression of VEGF, bFGF, IL-8, PDGF and angiostatin in relation to vascular density of xenografts in vivo. Int J Cancer 2000:86:768-76.
34. Ugurel S, Rappl G.Tilgen W, Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 2001;19:577-83.
35. Oliner J, Min H, Leal J, et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004;6:507-16.
36. Wang Y, Tasevski V, Wallace EM, Gallery ED, Morris JM. Reduced maternal serum concentrations of angiopoietin-2 in the first trimester precede intrauterine growth restriction associated with placental insufficiency. BJOG 2007;114:1427 -31.
37. Kuboki S, Shimizu H, Mitsuhashi N,et al. Angiopoietin- 2 levels in the hepatic vein as a useful predictor of tumor invasiveness and prognosis in human hepatocellular carcinoma. J Gastroenterol Hepatol 2008;23:e157 -64.
38. Brekken RA, Thorpe PE. VEGF-VEGF receptor complexes as markers of tumor vascular endothelium. J Control Release 2001;74:173-81.
39. Dias S, Hattori K, Heissig B, et al. Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci USA2001;98:10857 - 62.
40. Petrova TV, Bono P, HolnthonerW, et al. VEGFR-3 expression is restricted to blood and lymphatic vessels in solid tumors. Cancer Cell 2008;13:554-6.
41. Su JL, Chen PS, Chien MH, et al. Further evidence for expression and function of the VEGF-C/VEGFR-3 axis in cancer cells. Cancer Cell 2008;13:557-60.
42. Lin P, Polverini P, Dewhirst M, Shan S, Rao PS, Peters K. Inhibition of tumor angiogenesis using a soluble receptor establishes a role forTie2 in pathologic vascular growth. J Clin Invest 1997;100:2072-8.